Koji Izutsu

37PUBLICATIONS
156CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Apr 16, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

|Apr 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

Clémentine Sarkozy, Loïc Chartier, Vincent Ribrag

|Apr 03, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Guillaume Cartron, Roch Houot, Yassine Al Tabaa

|Mar 28, 2025
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.

Marta Canelo-Vilaseca, Mohamad Sabbah, Roberta Di Blasi

|Jan 08, 2025
T cell malignancies after CAR T cell therapy in the DESCAR-T registry.

Remy Dulery, Vincent Guiraud, Sylvain Choquet

|Sep 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Catherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres

Pageof 7

Frequent Collaborators

9 joint publications

Emmanuel Bachy

8 joint publications

René-Olivier Casasnovas

8 joint publications

Sylvain Choquet

7 joint publications

Roch Houot